Key risks
- Profit volatility is severe and unexplained: net profit swings from −₹1.79 Cr to ₹7.98 Cr across recent quarters despite nearly flat revenue (₹16–24 Cr range), creating EPS swings from −0.61 to 2.71; verify whether this reflects genuine business cycles or accounting inconsistencies.
- Operating margins lack predictability (3.36% to 10.75%), leaving minimal resilience to commodity shocks or competitive pricing pressure typical of generic pharmaceuticals.
- Stock has declined 60.61% over one year from ₹159 peak, paired with near-zero FII ownership (0%), signalling either a specific adverse catalyst or deep investor concern; verify recent regulatory filings and news for context.
- Small absolute scale (~₹90–100 Cr annualised revenue) limits negotiating leverage with suppliers and customers relative to larger domestic competitors.
Generated analysis · source review pending